Stock Events

Synlogic 

$1.55
0
+$0+0% Today

Statistics

Day High
1.55
Day Low
1.55
52W High
10.47
52W Low
1.47
Volume
75
Avg. Volume
707
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

14MayConfirmed
Q2 2022
Q3 2022
Q4 2022
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-2.67
-1.85
-1.03
-0.21
Expected EPS
-0.82
Actual EPS
-2.6

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0A8U.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap13.76B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, competing in the genetic medicine space similar to Synlogic's approach to synthetic biotics.
CRISPR Therapeutics
CRSP
Mkt Cap4.63B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the field of genetic and cellular therapies where Synlogic operates.
Editas Medicine
EDIT
Mkt Cap411.19M
Editas Medicine works on gene editing using CRISPR technology, directly competing with Synlogic in the development of novel genetic treatments.
Intellia Therapeutics
NTLA
Mkt Cap2.42B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing space, making it a competitor in the genetic therapy market.
Beam Therapeutics
BEAM
Mkt Cap2.14B
Beam Therapeutics focuses on precision genetic medicines using base editing, a next-generation CRISPR technology, competing in the same innovative healthcare sector.
Sangamo Therapeutics
SGMO
Mkt Cap82.4M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, gene editing, and gene regulation, positioning it as a competitor in the genetic treatment market.
Bluebird bio
BLUE
Mkt Cap114.8M
bluebird bio is focused on gene therapy for severe genetic diseases and cancer, competing with Synlogic in the advanced therapy medicinal products sector.
Regenxbio
RGNX
Mkt Cap619.64M
REGENXBIO is a leader in the development of AAV-based gene therapies, which places it in competition with companies developing other advanced genetic therapies.
Adverum Biotechnologies
ADVM
Mkt Cap169.58M
Adverum Biotechnologies is involved in gene therapy for ocular and rare diseases, competing in the broader field of genetic and cellular therapies.
Fate Therapeutics
FATE
Mkt Cap486.06M
Fate Therapeutics is focused on the development of programmed cellular immunotherapies for cancer and immune disorders, competing in the cell therapy space alongside Synlogic's synthetic biotics approach.

About

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; SYNB2081 to lower uric acid for the potential treatment of gout; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Employees
84
Country
United States
ISIN
US87166L2097
WKN
000A2DWU0

Listings